Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “buy” rating restated by analysts at Citigroup Inc. in a report released on Tuesday. They presently have a $150.00 price target on the biopharmaceutical company’s stock. Citigroup Inc.’s price objective indicates a potential upside of 56.66% from the company’s previous close.

ICPT has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price target (up from $60.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, August 8th. BMO Capital Markets reaffirmed an “outperform” rating and set a $221.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $200.00 price target on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, September 13th. Finally, Royal Bank of Canada began coverage on shares of Intercept Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $244.00 price target for the company. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $202.45.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.71% during midday trading on Tuesday, hitting $95.07. 462,165 shares of the stock traded hands. Intercept Pharmaceuticals has a one year low of $85.88 and a one year high of $172.95. The company’s market cap is $2.39 billion. The company’s 50-day moving average is $107.35 and its 200-day moving average is $115.96.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.62) by $0.16. The business had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The business’s revenue was up 459.6% on a year-over-year basis. During the same period last year, the business earned ($3.14) EPS. Equities research analysts expect that Intercept Pharmaceuticals will post ($13.91) EPS for the current fiscal year.

WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/19/intercept-pharmaceuticals-inc-icpt-receives-buy-rating-from-citigroup-inc.html.

In other news, CMO David Shapiro sold 1,250 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $117.43, for a total value of $146,787.50. Following the transaction, the chief marketing officer now directly owns 45,812 shares in the company, valued at approximately $5,379,703.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Sandip Kapadia sold 1,431 shares of the firm’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $121.59, for a total transaction of $173,995.29. Following the completion of the transaction, the chief financial officer now owns 20,569 shares in the company, valued at $2,500,984.71. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,013 shares of company stock worth $6,198,747. Insiders own 4.50% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. WFG Advisors LP lifted its position in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 125 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 132 shares during the last quarter. US Bancorp DE bought a new stake in Intercept Pharmaceuticals in the 1st quarter valued at about $130,000. IFP Advisors Inc lifted its position in Intercept Pharmaceuticals by 128.1% in the 2nd quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 730 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Intercept Pharmaceuticals in the 1st quarter valued at about $170,000. Institutional investors own 82.19% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.